Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;37(6):1265-1271.
doi: 10.1002/mds.28991. Epub 2022 Apr 1.

A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments

Anne-Marie Wills  1 , Alexander Pantelyat  2 , Alberto Espay  3 , James Chan  4 , Irene Litvan  5 , Tao Xie  6 , Marian L Dale  7 , Steven A Gunzler  8 , Maria Carmela Tartaglia  9 , Susan H Fox  10 , Federico Rodriguez-Porcel  11 , Mansi Sharma  12 , Anthony E Lang  10 , Adam L Boxer  13 ; AL-108-231 Study Group; Lawrence I Golbe  14
Affiliations

A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments

Anne-Marie Wills et al. Mov Disord. 2022 Jun.

Abstract

Background: The reliability of the Progressive Supranuclear Palsy Rating Scale (PSPRS) using teleneurology has not been assessed.

Objectives: To test whether removing items inadequately assessed by video would impact measurement of PSP severity and progression.

Methods: We performed secondary analyses of two data sets: the phase 2/3 trial of Davunetide in PSP and a large single-center cohort. We examined two modifications of the PSPRS: (1) removing neck rigidity, limb rigidity, and postural stability (25 items; mPSPRS-25) and (2) also removing three ocular motor items and limb dystonia (21 items; mPSPRS-21). Proportional agreement relative to the possible total scores was measured using the intraclass correlation coefficient, compared to the original PSPRS baseline values and change over 6 and 12 months. We examined the ability of both scales to predict survival in the single-center cohort using proportional hazards models.

Results: The mPSPRS-25 showed excellent agreement (0.99; P < 0.001) with the original PSPRS at baseline, 0.98 (P < 0.001) agreement in measuring change over 6 months, and 0.98 (P < 0.001) over 12 months. The mPSPRS-21 showed agreement of 0.94 (P < 0.001) with the original PSPRS at baseline, 0.92 (P < 0.001) at 6 months, and 0.95 (P < 0.001) at 12 months. Baseline and 6-month change in both modified scales were highly predictive of survival in the single-center cohort.

Conclusions: Modified versions of the PSPRS which can be administered remotely show excellent agreement with the original scale and predict survival in PSP. The mPSPRS-21 should facilitate clinical care and research in PSP via teleneurology. © 2022 International Parkinson and Movement Disorder Society.

Keywords: PSP; PSPRS; telemedicine; teleneurology; virtual.

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interest/financial disclosures: The authors have no relevant conflicts of interest.

Figures

FIG. 1.
FIG. 1.
Comparison between the modified and shortened version of the Progressive Supranuclear Palsy Rating Scale (PSPRS) and the total PSPRS at baseline and over time. Scatter plots comparing the 25-item and 21-item versions of the PSPRS to the total PSPRS score at baseline, change over 6 months, and 12 months. All scores are shown as proportions (0–1) of the total possible score (100 points for the 28-item PSPRS, 88 points for the mPSPRS-25, and 72 points for the mPSPRS-21). The black line demonstrates the line of agreement.
See this image and copyright information in PMC

Comment in

  • Recommendations for Virtual Administration of the PSP Rating Scale.
    Wills AM, Golbe LI, Lang AE, Xie T, Dale ML, Espay A, Tartaglia MC, Fox SH, Parashos SA, McFarland NR, Schneider RB, Rodriguez-Porcel F, Gunzler SA, Pantelyat A. Wills AM, et al. Mov Disord. 2022 Sep;37(9):1960-1961. doi: 10.1002/mds.29142. Epub 2022 Jul 10. Mov Disord. 2022. PMID: 35810447 Free PMC article. No abstract available.

References

    1. Naito A, Wills AM, Tropea TF, et al. Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. NPJ Parkinsons Dis 2021;7(1):34. - PMC - PubMed
    1. Koonin LM, Hoots B, Tsang CA, et al. Trends in the use of telehealth during the emergence of the COVID-19 pandemic - United States, January-March 2020. MMWR Morb Mortal Wkly Rep 2020;69(43):1595–1599. - PMC - PubMed
    1. Tarolli CG, Andrzejewski K, Zimmerman GA, et al. Feasibility, reliability, and value of remote video-based trial visits in Parkinson’s disease. J Parkinsons Dis 2020;10(4):1779–1786. - PubMed
    1. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency. In: https://www.fda.gov/media/136238/ download, published March 2020, updated August 2021.
    1. Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM. Potential reliability and validity of a modified version of the Unified Parkinson’s Disease Rating Scale that could be administered remotely. Parkinsonism Relat Disord 2013;19(2):218–221. - PMC - PubMed

Publication types

MeSH terms